Bank Of New York Mellon Corp Atossa Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.59 - $0.91 $89,255 - $137,664	151,280 New	151,280 $110 Million
Q4 2022 Feb 14, 2023	BUY	$0.5 - $1.01 $75,640 - $152,792	151,280 New	151,280 $80,000
Q2 2022 Aug 15, 2022	SELL	$0.85 - $1.28 $304,714 - $458,864	-358,488 Reduced 70.22%	152,052 $166,000
Q1 2022 May 11, 2022	SELL	$1.11 - $1.74 $10,120 - $15,865	-9,118 Reduced 1.75%	510,540 $639,000
Q4 2021 Feb 11, 2022	BUY	$1.6 - $3.27 $67,787 - $138,540	42,367 Added 8.88%	519,658 $832,000
Q3 2021 Nov 12, 2021	BUY	$2.89 - $6.4 $33,867 - $75,001	11,719 Added 2.52%	477,291 $1.56 Million
Q2 2021 Aug 11, 2021	BUY	$1.52 - $8.62 $653,060 - $3.7 Million	429,645 Added 1195.88%	465,572 $2.94 Million
Q1 2021 May 13, 2021	BUY	$0.92 - $4.33 $33,052 - $155,563	35,927 New	35,927 $75,000

26.5M

466K

91.8K

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $130M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.